Molecules 2009-01-01

A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.

Noboru Kubodera

Index: Molecules 14(10) , 3869-80, (2009)

Full Text: HTML

Abstract

Alfacalcidol (1alpha-hydroxyvitamin D(3)) has been widely used since 1981 as a prodrug for calcitriol (1alpha,25-dihydroxyvitamin D(3)) in the treatment of hypocalcemia, chronic renal failure, hypoparathyroidism and osteoporosis. More recently, doxercalciferol (1alpha-hydroxyvitamin D(2)) has been used since 1999 as a prodrug for 1alpha,25-dihydroxyvitamin D(2) for the treatment of secondary hyperparathyroidism. Currently, six forms of vitamin D are known. They range from vitamin D(2) to vitamin D(7 )and are distinguished by their differing side chains. Only vitamin D(2) and vitamin D(3) have been found to be biologically active based on the elucidation of activation pathways. Alfacalcidol and osteoporosis/doxercalciferol and secondary hyperparathyroidism are discussed, with a new look at old compounds including their practical syntheses.


Related Compounds

Related Articles:

[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].

2012-04-05

[MMW Fortschr. Med. 154 Suppl 1 , 10-21, (2012)]

Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study.

2014-05-01

[Int. J. Clin. Pharmacol. Ther. 52(5) , 360-8, (2014)]

Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroid-induced osteoporosis with alfacalcidol.

1999-10-01

[Calcif. Tissue Int. 65(4) , 317-27, (1999)]

Alfacalcidol enhances collagen quality in ovariectomized rat bones.

2014-08-01

[J. Orthop. Res. 32(8) , 1030-6, (2014)]

Is there a differential response to alfacalcidol and vitamin D in the treatment of osteoporosis?

1997-01-01

[Calcif. Tissue Int. 60(1) , 111-4, (1997)]

More Articles...